The Regional Prospective Observational Research in Tuberculosis - Brazil (RePORT-Brazil) network is pleased to announce its 1st Cohort of Fellows for the RePORT-Brazil Advanced Career Training (ReACT) program. Strategic Aim 3 of the recently renewed RePORT-Brazil Phase 2 grant (NIH U01AI172064-01), focuses on the development of a fellowship program for the advancement of early-career Brazilian scientists. The program provides funding for pilot projects in TB research, mentorship, and access to data and specimens collected throughout Phase 1 of the project.
Vanderbilt Tuberculosis Center recently hosted a meeting of researchers involved in our TB/HIV grant "Predictors of treatment toxicity, failure, and relapse in HIV-related tuberculosis" (NIH R01AI120790-04). The event, which took place on April 26th and 27th, included presentations on the results and findings of each working group, breakout sessions, and discussions on future steps to be taken and larger goals of the research.
Vanderbilt University Medical Center has been awarded a nearly $8 million grant from the National Institutes of Health to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms. When the renovation of about 3,500 square feet of existing space is completed, the facility will include three BSL3 suites with separate entrances and seven procedure rooms capable of securely containing multiple organisms at the second-highest biosafety level.
VUMC investigators and staff, Timothy Sterling, Yuri van der Heijden, Stephany Duda, Marina Figueiredo, Fernanda Mauri, Megan Turner, and Austin Katona; attended the annual RePORT International meeting that was held in Cape Town, South Africa, September 7 and 8, 2022. The meeting included all seven regions of RePORT: Brazil, China, South Africa, South Korea, India, Indonesia, and the Philippines. It was a successful meeting full of presentations and collaborative discussions.
We are pleased to announce the publication of “Cytomegalovirus Infection Is Associated With Increased Prevalence of Latent Tuberculosis Infection” in the Open Forum Infectious Diseases. This publication was led by Drs. Yuri F. van der Heijden and Moises A. Huaman.
The U.S. Centers for Disease Control and Prevention (CDC) Tuberculosis Trials Consortium (TBTC), together with collaborators from the National Institutes of Health’s (NIH) AIDS Clinical Trial Group (ACTG), is pleased to announce the publication of “Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis" in the New England Journal of Medicine.